Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block
NCT ID: NCT05793060
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
60 participants
INTERVENTIONAL
2025-08-01
2026-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives: To compare the safety and efficacy of dexmedetomidine versus dexamethasone as adjuvants to bupivacaine in ultrasound-guided intermediate cervical plexus block in patients undergoing total thyroidectomy under general anesthesia.
Patients and Methods: This is a randomized, double-blind, phase four, prospective clinical trial; carried out on 60 patients, who were candidates for total thyroidectomy under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received bilateral ICPB with isobaric bupivacaine plus dexmedetomidine, and group B, received bilateral ICPB with isobaric bupivacaine plus dexamethasone.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy
NCT02397603
Post- Thoracotomy Paravertebral Block
NCT02886429
The Efficacy of Adding Dexmedetomidine Perineurally to Bupivacaine in Ultrasound Guided Fascia Iliaca Block Versus Intravenously Infused Dexmedetomidine on Hemodynamic Stability Intraoperatively and Postoperative Analgesia Following Hip Arthroscopy
NCT04917029
Dexmedetomidine Versus Dexamethasone With Levobupivacaine in Interscalene Block
NCT03940469
Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade
NCT02049970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (n=30)
Dexmedetomidine group
Dexmedetomidine Hydrochloride
Dexmedetomidine 50 Mcg
Group B (n=30)
Dexamethasone group
Dexamethasone Phosphate
Dexamethasone 4 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine Hydrochloride
Dexmedetomidine 50 Mcg
Dexamethasone Phosphate
Dexamethasone 4 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age from 21 to 60 years
* Body Mass Index (BMI) ≤ 35 kg/m2
Exclusion Criteria
* Age \< 21 years or \> 50 years
* BMI \> 35 kg/m2
* Bronchial asthma
* Chronic obstructive pulmonary disease
* Restrictive lung diseases
* Sick sinus syndrome
* Sinus bradycardia
* Hypertension
* Chronic hypotension
* Ischemic heart disease
* Coagulopathies
* Hepatic insufficiency
* Renal insufficiency
* Diabetes mellitus
* Peripheral neuropathy
* Thyroid malignancy
* Hyperthyroidism
* Substernal goiter
* Patients on beta-blockers
* Patients using pacemakers
* Alcohol or drug abuse
* Allergy to the study drugs
21 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Damanhour Teaching Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed M Shaat, MD
Role: PRINCIPAL_INVESTIGATOR
Damanhour Teaching Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Damanhour Teaching Hospital
Damanhūr, El-Beheira, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DTH: 23001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.